New consortium widens search for antibiotic commercial models
This article was originally published in Scrip
Executive Summary
A number of big pharma firms have signed up to a new public-private consortium that will seek innovative economic models for pharma industry investment in antibiotic development, as well as defining a standard for the responsible use of existing antibiotics.